普拉洛芬滴眼液在青光眼手术前后炎症控制的临床评价

Clinical assessment of pranoprofen eye drops on preoperative and postoperative inflammation response of glaucoma surgery

摘要:

目的：通过观察青光眼手术前后应用普拉洛芬滴眼液对术后炎症反应的疗效，寻求一种青光眼术后炎症药物控制的较佳方案。

方法：观察青光眼小梁切除术的住院患者50例52眼，随机分为4组：术后单独滴用典必殊滴眼液组(甲组)、术后联合应用普拉洛芬眼液组(乙组)、术前1d始滴普拉洛芬滴眼液术后联合用药组(丙组)、术前3d始滴普拉洛芬滴眼液及术后联合用药组(丁组)。手术方法采用复合式小梁切除术。术后第 1，3，7，14，30d观察症状和体征并进行评分。

结果：患者50例52眼完成研究。术后第1，3d时丁组综合评分明显低于其它组(P<0.05)，术后3，7d时甲组综合评分比其它组均高(P<0.05)； 术后15d和30d时4组间综合评分差异无统计学意义(P>0.05)。

结论：术前应用普拉洛芬滴眼液做预处理，术后联合应用普拉洛芬滴眼液与糖皮质激素是青光眼小梁切除术后炎症控制的较佳治疗方案。

Abstract:

AIM:To seek a better drug therapy to control the inflammation after glaucoma surgery through observing the efficacy of using the pranoprofen eye drops before and after the glaucoma surgery.

METHODS:Totally 50 hospitalized cases(52 eyes)with trabeculectomy were randomly divided into 4 groups: a separate use of tobradex eye drops postoperatively(group A), combined tobradex with pranoprofen treatment postoperatively(group B), preoperative 1 day began to use pranoprofen eye drops, combined treatment after the operation group(group C), preoperative 3 day began to use the pranoprofen eye drops and postoperative combination therapy group(group D). Compound trabeculectomy was used as the surgical method. Signs and symptoms of postoperative 1 day, 3, 7, 14, 30 days were observed and scored. SPSS 18.0 statistical software was used for data processing. P <0.05 was considered statistically significant.

RESULTS:Totally 50 cases 52 eyes completed the study. Postoperative 1^st and 3^rd day, comprehensive score of group D was significantly lower than other groups(P<0.05). Comprehensive score of group A at postoperative 3 and 7 days was higher than any other group(P<0.05). Comprehensive score of 4 groups at postoperative 15 or 30 days had no statistical difference(P>0.05).

CONCLUSION: It is a better treatment option that inflammation after trabeculectomy treated by preoperative application of pranoprofen eye drops as pretreatment, postoperative combination of pranoprofen eye drops and glucocorticoid hormones.